Natasha Giusti, Author at Sanford Burnham Prebys - Page 7 of 34
Institute News

Q & A with Postdoctoral Researcher Ranajit Das, PhD, from the Cosford Lab

AuthorCommunications
Date

July 15, 2025

Meet one of our early-career scientists at Sanford Burnham Prebys: Ranajit Das, PhD, a postdoctoral researcher in the lab of Nicholas Cosford, PhD. Das is a medicinal chemist focused on designing and synthesizing new potential therapies, with a focus on cancer treatment.

When and how did you become interested in science?
During my early childhood education, I developed a deep curiosity about the world around me. Over time, I became more interested in chemistry. I found it fascinating that two colorless things can mix and make something colorful, or that two liquids can merge and produce a solid.

Then, when I was introduced to organic chemistry in my undergraduate years, it was eye-opening. I realized that organic chemistry is connected to nearly everything we use or do in our everyday lives. Everything from the blue dye in denim jeans to fading vegetable colors, fragrances, and even the medicines we take, are made of organic molecules. That realization drew me even deeper into the subject.

As I continued studying organic chemistry, I got into synthetic organic chemistry and building molecules. If you have the right knowledge, you can use simple building blocks that are usually made of carbon, hydrogen, nitrogen, and oxygen, and assemble them into compounds that can be functional, beautiful and even lifesaving.

How has your scientific career evolved?
While earning my master’s degree, I was learning about drug discovery and how organic molecules can be useful for treating human diseases. Then, during my PhD, I trained in how to use those chemical components to build a probe to study a disease and ascertain how to potentially cure that disease.

Ever since, I have wanted to build something which will improve human health. That is the reason I decided to pursue a scientific career.

What brought you to the Cosford lab at Sanford Burnham Prebys?
I chose to pursue my postdoctoral training at Sanford Burnham Prebys because of its strong emphasis on drug discovery. The Cosford lab has been working for almost two decades on a wide range of disease models—including cancer, central nervous system and infectious diseases—which are key areas in today’s therapeutic landscape.

This provides an unusual opportunity to gain practical experience with diverse targets. Furthermore, several of the lab’s drug candidates are in preclinical or phase I/II clinical trials, reflecting its strength in translational research.

What are the key areas of research you focus on?
Apoptosis, or programmed cell death, is a natural process in our body. It allows us to remove unwanted cells as we grow and develop. Cancer, however, can disrupt the system of apoptosis.

One way this happens is through the action of inhibitor of apoptosis proteins, which block caspases and help regulate cell survival and cell death during cancer. The second mitochondrial activator of caspases, or SMAC, can bind to and neutralize these inhibitor of apoptosis proteins, thereby promoting apoptosis.

We’re trying to make molecules that can mimic SMAC in order to treat cancer.

What motivates you about your research?
It’s the creativity and complexity around creating 3D chemical architecture to have potential medicinal properties. As we test and refine the compounds, I enjoy using my knowledge of how they react with protein molecules and how that affects the activity of those proteins, which can be useful for targeting diseases.

It is essential to nurture a feedback loop of biological activity and synthesis that keeps the drug discovery process dynamic and purposeful. For me, it is motivating to see that we are designing something and synthesizing something that is having the biological activity necessary for any potential candidate therapy. From there, we can work on finetuning in terms of potency, selectivity, pharmacodynamic stability and other characteristics of successful treatments.

What do you like about working here?
I like the collaborative and supportive research environment here at the institute. We have scientists and students from many different backgrounds and areas of expertise all focused on the same goal, the advancement of biomedical research.

The core research facilities and interdisciplinary expertise make this place ideal for pursuing very complicated targets for translational research. The Institute also has an emphasis on mentorship and career development, which is very important. I feel I’m growing as a scientist in a community which values curiosity, integrity and teamwork.

How would you describe the culture here?
There is a culture of open communication. Sharing ideas, discussing challenges and seeking feedback are encouraged. I’ve found this helps foster personal and professional growth, as well as scientific innovation.

What do you enjoy doing when you’re not in the lab?
I have a deep appreciation for world cinema, particularly Hollywood classics from the 80s and 90s. Bengali literature holds a special place in my heart, as does Indian classical music—especially the rich, melodic tones of the sitar and sarod.

Postdocs at Sanford Burnham Prebys are pushing the boundaries of science every day through curiosity, collaboration, and innovation. This series highlights their unique journeys, what inspires their work, and the impact they’re making across our labs.

Explore the Full Series

Institute News

Science in Pictures

AuthorScott LaFee
Date

July 14, 2025

A confocal micrograph of blood vessel networks in the intestine of an adult mouse.

Image courtesy of Satu Paavonsalo and Sinem Karaman, University of Helsinki.

Institute News

Science in Pictures

AuthorScott LaFee
Date

July 7, 2025

A fluorescent micrograph of a section of small intestine of a mouse. The finger-like projections are villi, which line the intestinal tract and increase surface area for absorption.

Image courtesy of Amy Engevik, Medical University of South Carolina.

Institute News

Science in Pictures

AuthorScott LaFee
Date

June 30, 2025

An optical projection tomograph depicts the lung of a 16 ½ day old embryonic mouse, with airways highlighted in pink and epithelial progenitors in green.

Image courtesy of Kamryn Gerner-Mauro and Jichao Chen at University of Texas MD Anderson Cancer Center.

Institute News

Science in Pictures

AuthorScott LaFee
Date

June 23, 2025

A trichinella cyst is depicted in pork muscle. Trichinella is a parasitic worm known to cause trichinosis, an intestinal infection that, untreated, can progress to serious inflammation of the heart and lungs.

Image courtesy of Nathan P. Myhrvold, Modernist Cuisine.

Institute News

Opinion: Health database could provide key insights to improve care

AuthorDavid A. Brenner
Date

June 23, 2025

In every body and in everybody, there is an enormous, diverse and changing array of medical and health information, from longitudinal data like our weight and blood pressure over the years to the biological samples, such as blood and tissues, that your doctor or a medical professional may ask you to provide.

There is also the non-medical social and demographic information that we share, from lifestyle choices like smoking, drinking and how much we exercise to socioeconomic status and how often we actually seek or need health care.

To some degree, we provide this information to our doctors during visits to clinics and hospitals. It’s part of how they work to keep each of us as healthy as possible.

But for everyone else, not so much, which is a shame.

The amount of health information collected by physicians is vast, unprecedented and exponentially growing, fueled by now-standard electronic health records (EHR) that make it easier, simpler and faster to collect and share patient information.

That last word “share” is critical. While having a digital record of your health is useful and convenient for individual doctors and patients, it is the untapped power and potential of new insights and discoveries lying within our combined health data that promises improved biomedical research and better answers to our relentless need for new drugs, treatments and therapies.

The term “translational medicine,” whose intent is to specifically apply basic scientific discoveries to human health, was introduced in the 1990s and gained widespread use through the emergence of popular terms like “bench-to-bedside” and “precision medicine” in the early 2000s.

But there is a massive gap between the generation of clinical data with its hidden treasures and the reality of companies and institutions leveraging those insights into new drugs and treatments that actually help people.

I know because I stand in that gap, a member of the scientific infrastructure necessary to translate research into health. I’m not alone, but it can sometimes feel like a lonely crusade.

Thanks to the biomedical revolution fueled by new technologies, we now have much deeper, empirically based understanding of how life works, from molecules and cells to networks of tissues and organs. Correspondingly, we better understand the pathology of disease, albeit not perfectly. There is still much to learn.

Where we always struggle is translating basic knowledge into action, into healthier and saved lives.

Humans are 99.9% identical in their genetic makeup. It is the remaining 0.1% that makes each of us unique. These genomic differences include “variances of uncertain significance.” or VUS. They are slight differences in DNA. Unlike gene variations specifically associated with disease, such as cystic fibrosis and sickle cell anemia, it is not clear whether variances of uncertain significances are actually connected to a specific health condition.

They are riddles wrapped in a mystery inside a cell membrane. We don’t know what variances of uncertain significances do, if they do anything, but within them perhaps lie many of the answers and remedies for what ails us.

Everyday clinics and hospitals collect human cells and tissue samples for examination. If a sample reveals a known, recognizable condition or disease, it can inform the physician about next treatment steps. If it does not, it is likely stored and ignored.

Doctors lack the expertise and capacity to study variances of uncertain significances in detail. Current and future biotechnology companies might have the expertise and ability to test and market new remedies, but they need someone to first to figure out how biology translates to medicine.

Some places, like where I work, already do this. It’s part of our vision and mission. The translational journey requires taking real steps. Systematically tapping the troves of clinical samples for new knowledge is one of them.

Another approach is to introduce the variances of uncertain significance into a preclinical model of a disease and see whether it makes the phenotype (the disease characteristics) worse. If the disease gets worse in the model system, the variances of uncertain significance is probably a disease causing mutation, if the disease is unchanged, the variances of uncertain significance is probably a harmless genetic variant.

Biomedical repositories and basic researchers can be doing more, collaborating more. The benefits are both certain and significant.

View the original piece in the San Diego Union-Tribune

Institute News

Science in Pictures

AuthorScott LaFee
Date

June 16, 2025

A micrograph using confocal, fluorescence and image stacking technologies depicts the optic nerve head of a rodent. Astrocytes in yellow, contractile proteins in red and vasculature in green.

Image courtesy of Hassanin Qambari and Jayden Dickson, Lions Eye Institute, Australia.

Institute News

Science in Pictures

AuthorScott LaFee
Date

June 9, 2025

A darkfield image of a mammal heart.

Image courtesy of Hillary Guzik, Rochester Institute of Technology.

Institute News

Sanford Burnham Prebys celebrates newest graduate school alumni

AuthorGreg Calhoun
Date

June 4, 2025

The Institute’s Graduate School of Biomedical Sciences held its second Commencement ceremony to celebrate four recent graduates

Family, friends and colleagues gathered at the end of May 2025 to applaud the four newest alumni of the Sanford Burnham Prebys Graduate School of Biomedical Sciences. These early-career scientists are the latest graduates to leave their mark on the institute and carry forth the graduate program’s motto, “Knowledge is the power to heal.”

On Friday, May 30, 2025, the Graduate School of Biomedical Sciences held its graduation ceremony at the institute’s La Jolla campus in the Victor E. LaFave III Memorial Auditorium.

“Each of you has made significant contributions to your field of science, created new knowledge and demonstrated the ability to perform independent research,” said Alessandra Sacco, PhD, dean of the institute’s graduate school and professor and director of the Development, Aging and Regeneration Program in the Center for Cardiovascular and Muscular Diseases.

“Today, we celebrate not only your academic journey, but also your years of dedication to get to this point, and the perseverance and intellectual curiosity that enabled you to reach this milestone.”

Following her remarks, Sacco introduced Ryan Loughran, PhD ’24, to speak on behalf of his fellow graduates.

“Graduate school is an experience unlike any other,” said Loughran. “You’re constantly drinking from a fire hose, learning new techniques, running experiments, coding data pipelines, writing and reviewing papers, preparing posters and giving talks.

‘I came to realize that it’s overwhelming by design. Somewhere in that chaos, something incredible happens. You’re forged by the fire. You begin to absorb information with an insatiable hunger. You think more critically and more creatively when confronting problems, and that is the true gift of the PhD experience.”

Loughran turned the podium over to Guy Salvesen, PhD, the inaugural dean of the graduate school, who provided the Commencement address.

“The graduates in front of you display the success of the program,” he said. “More importantly and more fundamentally, though, they have reached this milestone based on the merits of the hard-won accomplishments that they share with their mentors.”

Diane Klotz, PhD, chief learning officer at Sanford Burnham Prebys, then discussed the meaning of the hoods and symbols that are used in Commencement ceremonies. She invited the graduates forward and instructed faculty members to adorn them with the doctoral academic hoods signifying completion of a PhD program.

This year, the following graduates were recognized:

Andrei Osterman, PhD, the graduate school’s vice dean and associate dean of curriculum and a professor in the Center for Metabolic and Liver Diseases, provided the ceremony’s closing remarks.

“While today is primarily a celebration of individual intellectual achievements, it also recognizes your meaningful contributions to and interactions with the scientific community,” he said. “You have grown through peer review and collaborating with others, and these experiences will benefit you wherever your career takes you.”

More on this year’s graduates

Zong Ming Chua, PhD ’24, was born in Singapore. He developed a deep and early interest in biology after reading Darwin’s seminal work “On the Origin of Species” and various books by Richard Dawkins.

At Sanford Burnham Prebys, Zong Ming investigated the mechanisms that link cellular senescence and epigenetics. He discovered a new role of the histone variant H2A.Z R80C. He found that the histone variant influenced the transcriptomic profile of senescent cells.

Zong Ming moved to the Bay Area after graduating and is currently a computational biologist at GigaGen.

Jordan Friedlein, PhD ’24, was born and raised in Minnesota. From an early age, he expressed a desire to understand how the world worked. In high school, biology and physiology were his favorite classes.

Jordan joined the Bagchi Lab in 2019 and worked on investigating the role of circular RNA derived proteins in Myc-driven cancers. During his five years, Jordan enjoyed contributing to cutting-edge research and building lasting relationships with other grad students and institute members.

Ryan Loughran, PhD ’24, was born and raised in Greensburg, Penn. Growing up in a family with four generations of pharmacists, Ryan always imagined following in their footsteps and taking over the family-owned Loughran’s Pharmacy.

However, his path took a different turn during his undergraduate studies when he had the opportunity to spend a summer in New York City as an intern in the Emerling lab at Weill Cornell Medicine. He later moved with Emerling to help establish her new lab at Sanford Burnham Prebys as her lab manager. He later joined the Emerling lab as a graduate student.

Ryan plans to undertake a short postdoctoral position before transitioning into the pharmaceutical industry, where he aims to apply his knowledge and experience in cancer research to real-world applications.

Zhouting Zhu, PhD ’24, grew up in Changzhou city in the Jiangsu province of China. After completing a Master of Science in Surgery degree from Nanjing University in 2018, Zhouting joined the graduate program at Sanford Burnham Prebys.

She conducted her doctoral research in the lab of Tariq Rana, PhD, an educational affiliate professor in the Graduate School of Biomedical Sciences. Zhouting focused on RNA biology and cancer immunotherapy. Her work explored immune cell dynamics in tumors and spleens under various treatment conditions in mouse cancer models.

Zhouting is currently working toward MD-equivalency certification, with the long-term goal of becoming a board-certified physician-scientist.

Institute News

Science in Pictures

AuthorScott LaFee
Date

June 2, 2025

Purkinje neurons are located in the cerebellar cortex of the brain. With their flask-shaped cell bodies, many branching dendrites and a single long axon, these cells are essential for controlling motor activity.

Image courtesy of Thomas Deerinck, NCMIR, UC San Diego.